Activities

• 

  Mary Grace N. Tamio (Gra Sya)  

  on October 11 2023 at 02:31 PM Edited public

  Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas
  
  #immunohistochemistry #ovariancarcinoma #journals #articles
  
  More info | ⬇️
  https://social.cn1699.cn/livenewss/news/967678/Survey-of-NF1-inactivation-by-surrogate-immunohistochemistry-in-ovarian-carcinomas

  

  Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas | CN1699 Social

  The social Community for Global Healthcare Elites. Doctors, Medical Professionals & Pharmaceutical professionals. Medical Thesis Abstracts and...
  0 0 0 0 0 0 0

  comment Comment

  thumb_upLike

  share Share
• 

  Mary Grace N. Tamio   

  on August 15 2022 at 10:11 PM Edited public

  A Multistep Tumor Growth Model of High Grade Serous Ovarian Carcinoma Identifies Hypoxia Associated Signatures
  
  #tumor #ovariancarcinoma #hypoxia #journals #articles
  
  For more information | ⬇️
  https://social.cn1699.cn/livenewss/news/654753/A-Multistep-Tumor-Growth-Model-of-High-Grade-Serous-Ovarian-Carcinoma-Identifies-Hypoxia-Associated-Signatures

  

  A Multistep Tumor Growth Model of High Grade Serous Ovarian Carcinoma Identifies Hypoxia Associated Signatures | CN1699 Social

  The social Community for Global Healthcare Elites. Doctors, Medical Professionals & Pharmaceutical professionals. Medical Thesis Abstracts and...
  0 0 0 0 0 0 0

  comment Comment

  thumb_upLike

  share Share
• 

  Mary Grace N. Tamio   

  on February 04 2022 at 06:50 PM Edited public

  Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma
  
  #trametinib #ovariancarcinoma
  
  For more information | ⬇️
  https://cn1699.com/news/trametinib-represents-potential-new-standard-care-patients-recurrent-low-grade-serous-ovarian

  

  Trametinib represents potential new standard-of-care for patients with recurrent low-grade serous ovarian carcinoma | CN1699

  A study led by researchers at The University of Texas MD Anderson Cancer Center reported that the MEK inhibitor trametinib reduced the risk of...
  0 0 0 0 0 0 0

  comment Comment

  thumb_upLike

  share Share